ArticleJournal of chemical information and modeling2026
A Reproducible Hierarchical Virtual Screening Framework Integrating Scaffold-Aware Machine Learning, Ensemble Docking, and Molecular Dynamics: Application to IDO1.
Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Score: Fixed-Budget Benchmarking of Virtual Screening Integration Strategies for Decision-Centric Drug Discovery.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing enzyme implicated in cancer immune escape and remains an attractive therapeutic target despite recent clinical setbacks. We report a fully reproducible hierarchical virtual screening framework integrating scaffold-aware machine learning, ensemble docking, consensus scoring, and molecular dynamics simulations for robust prioritization of IDO1 inhibitors. A curated ChEMBL data set of IDO1 inhibitors was subjected to strict standardization, duplicate removal, and activity binarization at pChEMBL ≥6. Models were trained using scaffold-based splitting and nested cross-validation to prevent chemical series leakage. An ensemble of Random Forest, XGBoost and SVM classifiers achieved balanced predictive performance (ROC-AUC ≈0.88-0.89) with applicability domain filtering to ensure reliability. Prospective screening of FDA-approved drugs yielded 39 compounds within the applicability domain predicted as active. These were further evaluated through ensemble docking against multiple IDO1 crystal structures using GNINA with CNN rescoring. Consensus strategies were systematically benchmarked, demonstrating that best-Z-score aggregation outperformed mean, rank-based, and weighted methods in enrichment factor (EF) metrics. Two top-ranked candidates were subjected to 300 ns molecular dynamics simulations, revealing stable binding modes and persistent interactions with key catalytic residues. This study demonstrates that hierarchical integration of scaffold-aware machine learning with structure-based ensemble strategies enhances robustness and reduces false positives in virtual screening campaigns. The proposed workflow is generalizable and supports reproducible candidate prioritization in computational drug discovery. The complete implementation, including data processing, model training, and analysis steps, is provided as a fully executable Jupyter notebook available at https://github.com/rocco-b/IDO1-inhibitors-ML-and-docking-data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.